CAS 475-31-0|Glycocholic acid
Introduction：Basic information about CAS 475-31-0|Glycocholic acid, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Glycocholic acid | ||
|---|---|---|---|
| CAS Number | 475-31-0 | Molecular Weight | 465.623 |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 655.3±65.0 °C at 760 mmHg |
| Molecular Formula | C26H43NO6 | Melting Point | 128°C |
| MSDS | / | Flash Point | 350.1±34.3 °C |
Names
| Name | glycocholic acid |
|---|---|
| Synonym | More Synonyms |
Glycocholic acid BiologicalActivity
| Description | Glycocholic acid is a bile acid with anticancer activity, targeting against pump resistance-related and non-pump resistance-related pathways. |
|---|---|
| Related Catalog | Signaling Pathways >>Apoptosis >>Bcl-2 FamilyNatural Products >>Acids and AldehydesResearch Areas >>Cancer |
| Target | Human Endogenous Metabolite Bax Bcl-2 MDR1 MRP1 MDR2 |
| In Vitro | Glycocholic acid (GC) increases the cytotoxicity of epirubicin, significantly increases the intracellular accumulation of epirubicin in Caco-2 cells and the absorption of epirubicin in rat small intestine, and intensified epirubicin-induced apoptosis. Glycocholic acid and epirubicin significantly reduce mRNA expression levels of human intestinal MDR1, MDR-associated protein (MRP)1, and MRP2; downregulate the MDR1 promoter region; suppress the mRNA expression of Bcl-2; induce the mRNA expression of Bax; and significantly increase the Bax-to-Bcl-2 ratio and the mRNA levels of p53, caspase-9 and -3. A combination of anticancer drugs with Glycocholic acid can control MDR via a mechanism that involves modulating P-gp and MRPs as well as regulating apoptosis-related pathways[1]. |
| References | [1]. Lo YL, et al. Inhibit multidrug resistance and induce apoptosis by using glycocholic acid and epirubicin. Eur J Pharm Sci. 2008 Sep 2;35(1-2):52-67. |
Chemical & Physical Properties
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 655.3±65.0 °C at 760 mmHg |
| Melting Point | 128°C |
| Molecular Formula | C26H43NO6 |
| Molecular Weight | 465.623 |
| Flash Point | 350.1±34.3 °C |
| Exact Mass | 465.309052 |
| PSA | 127.09000 |
| LogP | 2.45 |
| Vapour Pressure | 0.0±4.5 mmHg at 25°C |
| Index of Refraction | 1.645 |
| InChIKey | RFDAIACWWDREDC-FRVQLJSFSA-N |
| SMILES | CC(CCC(=O)NCC(=O)O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CC(O)C12C |
| Storage condition | Refrigerator |
| Water Solubility | methanol: 0.1 g/mL, clear, colorless |
Safety Information
| Hazard Codes | N:Dangerousfortheenvironment; |
|---|---|
| Risk Phrases | R51/53 |
| Safety Phrases | S61 |
| RIDADR | UN 3077 9/PG 3 |
| WGK Germany | 3 |
Synonyms
| (Z)-N-[(3α,5β,7α,8ξ,12α,20R,24Z)-3,7,12,24-Tetrahydroxycholan-24-ylidene]glycine |
| Glycine, N-[(3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]- |
| N-choloyl-Glycine |
| Glycocholic Acid Hydrate |
| 3a,7a,12a-Trihydroxy-5b-cholan-24-oylglycine |
| Glycocholic acid |
| Glycine, N-[(3α,5β,7α,8ξ,12α,20R,24Z)-3,7,12,24-tetrahydroxycholan-24-ylidene]-, (Z)- |
| N-[(3α,5β,7α,12α)-3,7,12-Trihydroxy-24-oxocholan-24-yl]glycine |
| 2-[[(4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]acetic acid |
| N-Choloylglycine |
| N-[(3a,5b,7a,12a)-3,7,12-Trihydroxy-24-oxocholan-24-yl]glycine |
| EINECS 207-494-9 |
| ({(4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-Trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl}amino)acetic acid |
| MFCD06408004 |
| Glycine, N-((3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl)- |
